logo
Desperately ill baby healed with personalized gene therapy, doctors say

Desperately ill baby healed with personalized gene therapy, doctors say

CBC15-05-2025

A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him, according to the doctors who treated him.
Researchers described the case in a new study, saying he's among the first to be successfully treated with a custom therapy that seeks to fix a tiny but critical error in his genetic code that kills half of the infants with the rare disease. Though it may be a while before similar personalized treatments are available for others, doctors hope the technology can someday help the millions left behind even as genetic medicine has advanced because their conditions are so rare.
"This is the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which there are currently no definitive medical treatments," said Dr. Kiran Musunuru, a University of Pennsylvania gene editing expert who co-authored the study published Thursday in the New England Journal of Medicine.
The baby, KJ Muldoon of Clifton Heights, Penn., is one of 350 million people worldwide with rare diseases, most of which are genetic. He was diagnosed shortly after birth with severe CPS1 deficiency, estimated by some experts to affect around one in a million babies.
Those infants lack an enzyme needed to help remove ammonia from the body, so it can build up in their blood and become toxic. A liver transplant is an option for some.
Knowing KJ's odds, parents Kyle and Nicole Muldoon, both 34, worried they could lose him.
"We were, like, you know, weighing all the options, asking all the questions for either the liver transplant, which is invasive, or something that's never been done before," Nicole said.
"We prayed, we talked to people, we gathered information, and we eventually decided that this was the way we were going to go," her husband added.
Within six months, the team at Children's Hospital of Philadelphia and Penn Medicine, along with their partners, created a therapy designed to correct KJ's faulty gene. They used CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. Instead of cutting the DNA strand like the first CRISPR approaches, doctors employed a technique that flips the mutated DNA "letter" — also known as a base — to the correct type. Known as "base editing," it reduces the risk of unintended genetic changes.
It's "very exciting" that the team created the therapy so quickly, said gene therapy researcher Senthil Bhoopalan at St. Jude Children's Research Hospital in Memphis, who wasn't involved in the study. "This really sets the pace and the benchmark for such approaches."
In February, KJ got his first IV infusion with the gene editing therapy, delivered through tiny fatty droplets called lipid nanoparticles that are taken up by liver cells.
WATCH | Gene therapy for sickle cell:
U.K. approves world's first gene therapy treatment for sickle cell
1 year ago
Duration 2:03
While the room was abuzz with excitement that day, "he slept through the entire thing," recalled study author Dr. Rebecca Ahrens-Nicklas, a gene therapy expert at CHOP.
After follow-up doses in March and April, KJ has been able to eat more normally and has recovered well from illnesses like colds, which can strain the body and exacerbate symptoms of CPS1. The nine-and-a-half-month old also takes less medication.
Considering his poor prognosis earlier, "any time we see even the smallest milestone that he's meeting — like a little wave or rolling over — that's a big moment for us," his mother said.
Still, researchers caution that it's only been a few months. They'll need to watch him for years.
"We're still very much in the early stages of understanding what this medication may have done for KJ," Ahrens-Nicklas said. "But every day, he's showing us signs that he's growing and thriving."
Opens door to advances in other rare diseases
Researchers hope what they learn from KJ will help other rare disease patients.
Gene therapies, which can be extremely expensive to develop, generally target more common disorders in part for simple financial reasons: more patients mean potentially more sales, which can help pay the development costs and generate more profit. The first CRISPR therapy approved by the U.S. Food and Drug Administration, for example, treats sickle cell disease, a painful blood disorder affecting millions worldwide.
Musunuru said his team's work — funded in part by the U.S. National Institutes of Health — showed that creating a custom treatment doesn't have to be prohibitively expensive. The cost was "not far off" from the $800,000 US-plus for an average liver transplant and related care, he said.
"As we get better and better at making these therapies and shorten the time frame even more, economies of scale will kick in and I would expect the costs to come down," Musunuru said.
Scientists also won't have to redo all the initial work every time they create a customized therapy, Bhoopalan said, so this research "sets the stage" for treating other rare conditions.
Carlos Moraes, a neurology professor at the University of Miami who wasn't involved with the study, said research like this opens the door to more advances.
"Once someone comes with a breakthrough like this, it will take no time" for other teams to apply the lessons and move forward, he said. "There are barriers, but I predict that they are going to be crossed in the next five to 10 years. Then the whole field will move as a block because we're pretty much ready."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?
PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?

Globe and Mail

time13 minutes ago

  • Globe and Mail

PepsiCo Leans on Gatorade & LIFEWTR: Can Wellness Fuel Growth?

PepsiCo, Inc. 's PEP hydration portfolio is anchored by Gatorade and LIFEWTR, two brands that reflect its strategic shift toward functional performance and premium wellness offerings. In first-quarter 2025, Gatorade remained a strong performer, especially with innovations like Gatorade Zero and new rapid hydration products. The company is also investing in powders, tablets and other functional hydration options to meet evolving health and wellness demands. Gatorade's ongoing expansion into performance-focused formats is helping it regain its share in the competitive sports drink market. LIFEWTR, PepsiCo's premium bottled water brand, is another pillar of the company's health-focused strategy. Positioned as a wellness-driven offering, LIFEWTR taps into the growing consumer interest in premium hydration with clean ingredients and lifestyle-oriented branding. The brand's continued double-digit growth demonstrates strong traction, supporting PepsiCo's broader efforts to diversify away from traditional sugary beverages. This approach aligns with the company's intention to offer more permissible, functional beverages across a range of consumer occasions. Complementing these efforts is PepsiCo's broader shift toward 'better-for-you' portfolios, which include investments in protein, fiber and reduced sugar offerings. Notably, the company is innovating in protein-enriched beverages and snacks, aiming to capture value in emerging consumption trends, such as those driven by GLP-1 medication users seeking smaller portions and nutrient-dense foods. With consumer demand moving toward healthier, more functional products, PepsiCo's strategy of doubling down on brands like Gatorade and LIFEWTR positions it well for sustained growth in the wellness space. PEP's Competition in the Wellness Space The Coca-Cola Company KO and Keurig Dr Pepper KDP are the key beverage companies competing with PepsiCo in the global arena. The Coca-Cola Company is strategically reinforcing its hydration and wellness lineup to compete directly with PepsiCo's Gatorade and LIFEWTR by leveraging brands like Powerade, Smartwater and Vitaminwater. Powerade has been revamped with a focus on innovation in performance hydration, incorporating enhanced electrolytes and new formulations to target athletes and fitness enthusiasts. Smartwater and Vitaminwater continue to lead Coca-Cola's charge in the premium and functional beverage segments, respectively, offering vapor-distilled purity and added nutrients. The company is also investing in digital marketing, packaging personalization and local relevance campaigns to build consumer trust and loyalty. With 30 billion-dollar brands in its portfolio and 68% of its drinks containing fewer than 100 calories per serving, Coca-Cola is aligning with health trends through innovation and consumer-centric strategies, positioning itself as a strong challenger to PepsiCo's hydration dominance. Keurig Dr Pepper competes aggressively with PepsiCo in the hydration and wellness space through brands like Core Hydration and Snapple Elements, focusing on functional benefits and health-conscious positioning. KDP's strategy centers on leveraging consumer trends such as low-calorie, antioxidant-rich and pH-balanced beverages, positioning Core as a premium hydration brand. Innovation remains a cornerstone of its approach, with ongoing flavor expansions, clean-label formulations and sleek packaging aimed at wellness-driven Millennials and Gen Z consumers. By capitalizing on its broad distribution network and agile marketing, KDP is carving out a strong niche against PepsiCo's Gatorade and LIFEWTR, appealing to consumers looking for alternatives with perceived health benefits and contemporary branding. PEP's Price Performance, Valuation and Estimates Shares of PepsiCo have lost around 14.5% year to date against the industry 's growth of 7.6%. From a valuation standpoint, PEP trades at a forward price-to-earnings ratio of 16.13X, significantly below the industry's average of 18.68X. The Zacks Consensus Estimate for PEP's 2025 earnings implies a year-over-year decline of 3.6%, whereas its 2026 earnings estimate suggests year-over-year growth of 5.4%. The estimates for 2025 and 2026 have been southbound in the past 30 days. PEP stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CocaCola Company (The) (KO): Free Stock Analysis Report PepsiCo, Inc. (PEP): Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP): Free Stock Analysis Report

Vaccine stocks muted as investors assess Kennedy's overhaul of key panel
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel

Globe and Mail

time40 minutes ago

  • Globe and Mail

Vaccine stocks muted as investors assess Kennedy's overhaul of key panel

Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s surprising decision to fire all 17 members of a key expert panel late on Monday. Shares of U.S. vaccine maker Moderna (MRNA-Q) fell 2 per cent while Novavax (NVAX-Q) was down marginally. Merck (MRX-N) and Pfizer (PFE-N) rose between 1.4 per cent and 2 per cent. European shares of AstraZeneca (AZN-Q) closed slightly higher, while BioNTech (BNTX-Q) closed marginally lower. Analysts and investors said that while the unprecedented dismissals of all members of the Advisory Committee on Immunization Practices (ACIP) represented a risk for vaccine makers, the weak performance of those stocks in 2025 suggested that Kennedy's skepticism around vaccines was already factored in. Shares of most big drugmakers are down in 2025, compared with a 2-per-cent gain in the S&P 500 index. Since his appointment as health secretary under President Donald Trump, Kennedy has made several changes to reshape the regulation of vaccines, food and medicine. However, firing members of the ACIP remains his most far-reaching move yet. 'For vaccine makers, policy risk has already been cemented into share prices,' Morningstar analyst Karen Anderson said, even though the move was sudden and went against the promises that Kennedy made to Senator Bill Cassidy before his appointment was confirmed. Mr. Kennedy's decision comes less than three weeks before the next panel meeting, where the committee is slated to discuss recommendations for who should receive vaccines for diseases like respiratory syncytial virus, or RSV. 'It seems difficult to refill the panel with experts before the June 25th meeting,' said Jeff Jonas, portfolio manager at Gabelli Funds. 'But it's clearly going to be more difficult and more expensive to get future vaccines approved, and I'd expect to see less industry focus and effort here,' Jonas added, despite recent positive news such as the limited approval of Novavax's COVID shot and Merck's RSV therapy. Some analysts expressed concerns that the new committee members, who have not been named, might be more sympathetic to Mr. Kennedy's views on vaccines, an idea shared by scientific experts and doctors. Although the makeup of a reconstituted ACIP is yet to be determined, 'new members will likely be sympathetic to at least some of RFK's beliefs regarding alleged dangers of vaccines,' Leerink analyst Daina Graybosch wrote in a note. Ms. Graybosch said that the move could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development. It is unclear when Mr. Kennedy will announce the new members, who the agency said are under consideration, or whether the agenda will follow the meeting description posted on the Federal Register on Monday. Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.

Mike Tyson issues grim warning about dangers of drug use, fentanyl
Mike Tyson issues grim warning about dangers of drug use, fentanyl

National Post

timean hour ago

  • National Post

Mike Tyson issues grim warning about dangers of drug use, fentanyl

Once known as the Baddest Man on the Planet, Mike Tyson now is warning people about one of the most dangerous drugs on planet. Article content The legendary boxer, who knows his fair share about elicit drug use, spoke out about fentanyl during a tour of a U.S. Drug Enforcement Agency (DEA) lab in New York City earlier this week. Article content Article content Tyson toured the facility with Alina Habba, the acting U.S. Attorney for New Jersey, and even donned a DEA lab coat as he learned about the deadly narcotic. Article content 'One pill can kill,' Tyson told the New York Post. Article content 'I just found out that a pin of fentanyl can kill somebody. I was never educated on fentanyl and this is new to me. I'm just here to be educated on the laws.' Article content The 58-year-old former heavyweight champion owns a legal cannabis company, TYSON 2.0, and touted the safety of its products compared to street drugs potential laced with deadly narcotics. Article content According to reports, nearly 70% of recent overdose deaths in the U.S. have been attributed to illegally manufactured fentanyl and New York City saw nearly 2,200 fatal overdoses last year. Article content Article content 'There is a real toxic problem and that's the truth of it,' said Habba, who became friends with Tyson and his wife Kiki after meeting at a UFC event. Article content 'They are such proponents, the Tysons, of safe use. And making sure it's not from China or a pesticide.' Article content During the tour of the lab, Tyson was shown huge amounts of evidence collected in DEA seizures, including massive bags of marijuana, psychedelic mushrooms, vapes and a bag filled with orange-coloured fake Adderall. Article content A scientist showed off a fentanyl brick that also contained carfentanil, 'which is more potent than fentanyl,' Tyson was told. Article content Article content 'We have kids where they take a pill from God knows where or smoke a vape or take a gummy and they don't know where it came from and next thing you know you are on the floor because of that little piece of fentanyl,' Habba told Tyson. Article content Tyson's history with substance abuse is well-documented and a big reason why he became interested in legal, safe cannabis. Article content 'It's mostly because I was in a lot of insane asylums, believe it or not,' he said. 'I did a lot of drugs, a lot of cocaine and a lot of drinking and then I started smoking and it changed my whole life. Article content 'I haven't been smoking (cigarettes), I haven't been drinking, I haven't done cocaine in nine years,' he said. 'Now, I'm trying to make the whole cannabis universe safe.' Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store